People

Sarah Chapin Columbia

Partner
Areas of focus

Serves as lead trial counsel in patent infringement, trade secrets, and invalidity litigation across multiple federal jurisdictions

Counsels clients on overall intellectual property strategy and positioning, including litigation avoidance

Provides strategic IP guidance in complex transactions where intellectual property assets are critical to the deal

Advises clients across pharma/biotech, internet, semiconductor, hardware and software, medical device, and manufacturing industries

Sarah Chapin Columbia is a Fellow of the American College of Trial Lawyers. Over the last dozen years, she has led 17 patent infringement, trade secrets, and invalidity trials (11 jury trials and six bench trials) across several jurisdictions, including the federal courts in Massachusetts, Florida, Delaware, Colorado, California, and Texas.

See more

“Sarah is incredibly smart and careful. She gives actionable and thoughtful advice and we trust her implicitly.”

The Best Lawyers in America, Lawyer of the Year in Boston: Litigatio

The Best Lawyers in America, Lawyer of the Year in Boston: Litigatio

Chambers USA, Intellectual Property, Band 1, Massachusetts

Chambers USA, Intellectual Property, Band 1, Massachusetts

Forbes, America’s Best-In-State Lawyer

Forbes, America’s Best-In-State Lawyer

Results
  • Lead counsel for Alnylam in ongoing patent infringement litigation involving the cationic lipids essential to the delivery of the COVID-19 vaccines (Alnylam v. Pfizer/BionTech (D. Delaware); Alnylam v. Moderna (D. Delaware))
  • Lead counsel for Next Caller in simultaneous patent infringement litigation and trade secrets, tortious interference and breach of contract litigation related to authentication services. Successfully secured a unanimous jury verdict in favor of Next Caller in both matters (TrustID Inc. v. Next Caller Inc., (D. Delaware), TRUSTID, Inc. v. Next Caller Inc., (D. Colorado))
  • Lead counsel for Amgen in a patent infringement action and jury trials involving breakthrough biologic therapy for the treatment of high LDL cholesterol (Amgen v. Sanofi, et al., (D. Delaware))

See more

Recognitions
  • LMG Life Sciences, Shortlisted, General Patent Litigator of the Year – New England – 2026
  • Chambers USA, Intellectual Property, Band 1 (Massachusetts) and Band 3 (Nationwide), 2008-2026; Life Sciences, Band 3 (Massachusetts), 2026
  • The Best Lawyers in America, Lawyer of the Year in Boston: Litigation – Intellectual Property, 2022 and 2024-2026

See more

Capabilities and industries
Regional markets
Community
  • The Sedona Conference®, Working Group on Patent Damages and Remedies
Credentials
Education
  • Harvard Law School, JD, magna cum laude
  • Harvard University, MPP
  • Wesleyan University, BA, Economics
Admissions
  • Massachusetts
Courts/Agencies
  • Supreme Court of the United States
  • US Court of Appeals for the Federal Circuit
  • US Court of Appeals for the First Circuit
  • US Court of Appeals for the Second Circuit
  • US Court of Appeals for the Ninth Circuit
Languages
  • English